Humana Inc. (NYSE:HUM – Free Report) – Equities researchers at Zacks Research lowered their Q3 2025 earnings per share (EPS) estimates for Humana in a research report issued on Thursday, September 19th. Zacks Research analyst D. Chatterjee now expects that the insurance provider will post earnings per share of $4.83 for the quarter, down from their prior forecast of $4.84. The consensus estimate for Humana’s current full-year earnings is $16.00 per share. Zacks Research also issued estimates for Humana’s Q4 2025 earnings at $1.61 EPS.
Humana (NYSE:HUM – Get Free Report) last posted its quarterly earnings results on Wednesday, July 31st. The insurance provider reported $6.96 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.89 by $1.07. The firm had revenue of $29.54 billion for the quarter, compared to analyst estimates of $28.52 billion. Humana had a net margin of 1.53% and a return on equity of 16.12%. The company’s quarterly revenue was up 10.4% compared to the same quarter last year. During the same period in the prior year, the firm posted $8.94 earnings per share.
View Our Latest Stock Report on Humana
Humana Trading Down 0.5 %
Shares of HUM opened at $310.41 on Monday. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.66 and a current ratio of 1.66. Humana has a 52-week low of $298.61 and a 52-week high of $530.54. The firm has a market cap of $37.40 billion, a price-to-earnings ratio of 19.33, a PEG ratio of 2.56 and a beta of 0.50. The business’s fifty day moving average is $357.71 and its 200-day moving average is $345.60.
Humana Dividend Announcement
The firm also recently announced a quarterly dividend, which will be paid on Friday, October 25th. Stockholders of record on Monday, September 30th will be paid a $0.885 dividend. The ex-dividend date is Monday, September 30th. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.14%. Humana’s payout ratio is presently 22.04%.
Hedge Funds Weigh In On Humana
Several institutional investors have recently modified their holdings of the business. Trexquant Investment LP bought a new stake in shares of Humana during the 4th quarter worth $2,099,000. Quest Partners LLC bought a new stake in Humana in the fourth quarter worth about $128,000. Cambridge Investment Research Advisors Inc. boosted its stake in Humana by 12.3% in the fourth quarter. Cambridge Investment Research Advisors Inc. now owns 10,323 shares of the insurance provider’s stock valued at $4,726,000 after acquiring an additional 1,127 shares during the last quarter. SageView Advisory Group LLC bought a new position in shares of Humana during the 4th quarter valued at approximately $652,000. Finally, Advisory Services Network LLC grew its position in shares of Humana by 271.8% during the 4th quarter. Advisory Services Network LLC now owns 3,963 shares of the insurance provider’s stock valued at $1,815,000 after acquiring an additional 2,897 shares during the period. 92.38% of the stock is owned by institutional investors.
Humana Company Profile
Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.
Further Reading
- Five stocks we like better than Humana
- The Basics of Support and Resistance
- 3 Stocks That Could Rise on European Bank Interest Rate Cuts
- What is a support level?
- Take Advantage of Village Farms Stock as Cannabis Market Evolves
- Differences Between Momentum Investing and Long Term Investing
- MarketBeat Week in Review – 9/16 – 9/20
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.